#1 Clinical Trials Search in Europe

Mitoxantrone

Mitoxantrone is a powerful drug being studied in clinical trials for its potential to treat various medical conditions. These trials aim to evaluate the drug’s effectiveness, safety, and optimal dosing in diseases ranging from cancer to autoimmune disorders. Researchers are investigating how Mitoxantrone can be used alone or in combination with other treatments to improve patient outcomes and quality of life.

Table of Contents

What is Mitoxantrone?

Mitoxantrone is a powerful anti-cancer drug that belongs to a class of medications called antineoplastics or chemotherapy drugs. It is also known by its brand name Novantrone[10]. Mitoxantrone is used in various forms of cancer treatment and has also shown effectiveness in treating certain neurological conditions.

What Conditions Does Mitoxantrone Treat?

Mitoxantrone is used to treat several types of cancers and other medical conditions, including:

  • Breast Cancer: It is used in the treatment of advanced or metastatic breast cancer[1][4].
  • Leukemia: Mitoxantrone is effective against various types of leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)[2][3][5].
  • Lymphoma: It is used in treating certain types of lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and peripheral T/NK cell lymphomas[8].
  • Prostate Cancer: Mitoxantrone is approved for treating symptoms in advanced prostate cancer, particularly for bone pain relief[10].
  • Neuromyelitis Optica: This is a rare neurological condition where mitoxantrone has shown effectiveness[9].

How Does Mitoxantrone Work?

Mitoxantrone works by interfering with the DNA (genetic material) of cancer cells. It stops these cells from dividing and multiplying, which ultimately leads to their death. This mechanism helps to slow down or stop the growth of tumors and cancer spread[1].

In neurological conditions like neuromyelitis optica, mitoxantrone is believed to work by suppressing the immune system, which can help reduce inflammation and damage to the nervous system[9].

How is Mitoxantrone Administered?

Mitoxantrone is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency of administration can vary depending on the condition being treated and the patient’s individual factors. Some common administration methods include:

  • Every 3 weeks for a set number of cycles[1].
  • Weekly administrations for several weeks, followed by a rest period[10].
  • Every 3 months for a period of 2 years (in some neurological conditions)[9].

Mitoxantrone in Combination Therapies

Mitoxantrone is often used in combination with other drugs to enhance its effectiveness. Some common combinations include:

  • Mitoxantrone with docetaxel for breast cancer[1].
  • Mitoxantrone with etoposide and cytarabine for leukemia[2].
  • Mitoxantrone with cyclophosphamide, methotrexate, and fluorouracil for breast cancer[4].
  • Mitoxantrone with bortezomib for prostate cancer[10].

Potential Side Effects

Like all powerful medications, mitoxantrone can cause side effects. Some potential side effects include:

  • Lowered blood cell counts, which can increase the risk of infections and bleeding[2].
  • Nausea and vomiting
  • Hair loss
  • Fatigue
  • Potential heart problems, which is why heart function is monitored during treatment[9].

Your healthcare team will monitor you closely for these and other side effects during treatment.

Ongoing Research and Future Directions

Researchers continue to study mitoxantrone to find new ways to use it effectively and safely. Some areas of ongoing research include:

  • Development of liposomal formulations of mitoxantrone, which may help reduce side effects and improve efficacy[6].
  • Exploring new combination therapies to enhance the effectiveness of mitoxantrone in various cancers[5][10].
  • Investigating the use of mitoxantrone in other conditions, such as multiple sclerosis and other autoimmune diseases.

As with any medication, it’s crucial to discuss the potential benefits and risks of mitoxantrone with your healthcare provider. They can provide personalized information based on your specific medical condition and overall health status.

Aspect Details
Conditions Studied Solid tumors, lymphomas, prostate cancer, neuromyelitis optica, multiple sclerosis
Administration Intravenous (IV), doses ranging from 6-20 mg/m²
Frequency Every 3-4 weeks, depending on the trial
Duration Varies from months to years (up to 5 years in some trials)
Primary Outcomes Maximum tolerated dose, objective response rate, progression-free survival
Secondary Outcomes Overall survival, time to progression, safety profile
Combinations Studied alone and in combination with other drugs (e.g., Bortezomib, Cetuximab)
Safety Monitoring Cardiac function, blood cell counts, infections

FAQ

  • What is Mitoxantrone? Mitoxantrone is a synthetic drug that belongs to the anthracenedione class. It is used in medical treatments and is being studied for its potential in treating various conditions, including certain types of cancer and autoimmune diseases.
  • What conditions is Mitoxantrone being studied for in clinical trials? Clinical trials are investigating Mitoxantrone for several conditions, including solid tumors, lymphomas, prostate cancer, neuromyelitis optica, multiple sclerosis, and androgen-independent prostate cancer.
  • How is Mitoxantrone administered in these trials? In most trials, Mitoxantrone is administered intravenously (IV). The dosage and frequency vary depending on the specific trial and condition being studied. For example, some trials use doses ranging from 6-20 mg/m² given every 3-4 weeks.
  • What are some potential side effects of Mitoxantrone? While side effects can vary, some potential side effects being monitored in trials include cardiac effects, changes in blood cell counts, and infections. Trials are specifically designed to assess the safety profile and tolerability of Mitoxantrone.
  • How long do these clinical trials typically last? The duration of clinical trials for Mitoxantrone varies. Some trials last for a few months, while others may continue for several years. For example, some studies follow patients for up to 24 months or even 5 years to assess long-term outcomes and safety.

Ongoing Clinical Trials on Mitoxantrone

  • Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia Finland France Germany +5

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Daunorubicin, Mitoxantrone, and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Finland The Netherlands Norway Spain +1

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Estonia Finland Iceland Latvia +6

  • Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +13

  • Study Comparing Venetoclax and Azacitidine with Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutations Eligible for Intensive Treatment

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +5

  • Study of gemtuzumab ozogamicin and chemotherapy combinations in children with newly diagnosed acute myeloid leukemia, high-risk myelodysplastic syndrome, or myeloid sarcoma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Ireland

  • Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Czechia Germany Italy Poland Slovenia

Glossary

  • Mitoxantrone: A synthetic drug used in medical treatments, particularly for certain types of cancer and autoimmune diseases. It belongs to the anthracenedione class of medications.
  • Clinical Trial: A research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or level of treatment.
  • Maximum tolerated dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • Progression-free survival (PFS): The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment for a disease that patients diagnosed with the disease are still alive.
  • Objective response rate (ORR): The proportion of patients with tumor size reduction of a predefined amount and for a minimum time period.
  • Prostate-specific antigen (PSA): A protein produced by normal and malignant cells of the prostate gland. The PSA test measures the level of PSA in a man's blood.

References

  1. https://clinicaltrials.gov/study/NCT00002544
  2. https://clinicaltrials.gov/study/NCT00002912
  3. https://clinicaltrials.gov/study/NCT00002688
  4. https://clinicaltrials.gov/study/NCT00002498
  5. https://clinicaltrials.gov/study/NCT00940524
  6. https://clinicaltrials.gov/study/NCT02043756
  7. https://clinicaltrials.gov/study/NCT00002674
  8. https://clinicaltrials.gov/study/NCT02597387
  9. https://clinicaltrials.gov/study/NCT02021825
  10. https://clinicaltrials.gov/study/NCT00059631